Welcome to our dedicated page for Concentra Group Holdings Parent SEC filings (Ticker: CON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Concentra Group Holdings Parent's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Concentra Group Holdings Parent's regulatory disclosures and financial reporting.
BlackRock, Inc. reports beneficial ownership of 17,569,590 shares of CONCENTRA GROUP HOLDINGS PARENT INC common stock, representing 13.7% of the class. BlackRock has sole voting power over 17,378,159 shares and sole dispositive power over 17,569,590 shares, with no shared voting or dispositive power reported.
The filing explains that these holdings reflect securities beneficially owned, or deemed beneficially owned, by certain business units of BlackRock and its subsidiaries. One underlying holder, iShares Core S&P Small-Cap ETF, has an interest in Concentra common stock exceeding five percent of the total outstanding common stock.
Concentra Group Holdings Parent, Inc. outlined post-retirement arrangements for Executive Vice President and Chief Medical Officer Dr. John R. Anderson. Following his previously disclosed retirement effective December 31, 2026, Dr. Anderson will transition to a part-time consulting role with subsidiary Concentra Health Services, Inc.
The consulting agreement is effective from January 1, 2027 through December 31, 2027, with either party able to terminate on 30 days’ notice and Concentra able to terminate immediately for Cause. Dr. Anderson will provide up to 10 hours of consulting services per week at $216.00 per hour, and his outstanding unvested restricted stock awards under the 2024 Equity Incentive Plan will continue to vest during the term while he provides services. If he completes the term without termination for Cause or voluntary resignation, 25% of his then-unvested restricted stock will vest, while all unvested equity will be forfeited upon earlier termination for Cause or voluntary resignation, subject to execution of specified releases.
Concentra Group Holdings Parent, Inc. director Robert A. Ortenzio reported an indirect open-market sale of 130,000 shares of common stock on July 1, 2026 at a weighted average price of $30.4969 per share. The sale was executed by The Rocco A. Ortenzio Separate Descendants Trust for the benefit of Robert Ortenzio, which held 633,455 shares after the transaction. Additional indirect holdings are shown in several family trusts, and a separate line reflects 5,533,794 shares held directly as of the same date.
The filing is a Form 144 notice for proposed sales of Common Stock by trusts related to Rocco A. Ortenzio. It lists multiple proposed dispositions: two 130,000-share blocks reported on 05/08/2026 and 06/01/2026, and smaller dispositions in late June 2026 with specific share counts and dollar amounts.
CON: Notice of proposed resale of Common Stock under Form 144. The excerpt lists proposed sales and recent sales of Common shares by trusts associated with Rocco A. Ortenzio. It shows multiple dispositions of Common stock on 05/08/2026, 06/01/2026, 06/26/2026, and 06/29/2026 with reported share counts and gross proceeds for each transaction.
The filing records a prior private purchase dated 10/26/2024 and identifies UBS Financial Services Inc., Eleven Madison Avenue, New York, NY as the broker/agent. The filing is a regulatory notice of intended sales under Form 144 and does not state timing beyond the listed dates.
CON reported insider sales of Common Stock by trusts associated with Rocco A. Ortenzio. The filing lists three transactions: 130,000 shares sold on 05/08/2026, 130,000 shares sold on 06/01/2026, and 53,527 shares sold on 06/26/2026.
The entries identify the selling trusts and show aggregate proceeds reported for each trade in dollar amounts alongside the transaction dates.
The Rocco A Ortenzio Trust filed proposed sales of Common Stock of CON. The excerpt lists two proposed sales of 130,000 shares each, dated 05/08/2026 and 06/01/2026, with corresponding dollar figures $3,250,000.00 and $3,250,026.00.
The filings identify UBS Financial Services, Inc. at Eleven Madison Avenue, New York, NY, and reference a Private Purchase of Stock on 10/26/2024. The listed transactions are sales notifications under the Form 144/A process.
CON filed a Form 144 reporting proposed resales of Common Stock by an affiliate.
The filing lists two proposed dispositions by The Rocco A Ortenzio Trust FBO Robert Ortenzio: 130,000 shares on 05/08/2026 for $3,250,000 and 130,000 shares on 06/01/2026 for $3,250,026. Shares outstanding were 127,961,780 as of 06/26/2026.
Concentra Group Holdings Parent, Inc. director Robert A. Ortenzio reported an indirect open-market sale of 130,000 shares of Common Stock on June 1, 2026 by The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio.
The shares were sold at a weighted average price of $25.0002 per share, with individual sale prices ranging from $25.00 to $25.03. Following this transaction, the trust still holds 763,455 shares of Common Stock.
Additional entries show indirect holdings of 226,286 shares in each of several 2014 trusts and 1,032,115 shares in the Robert A. Ortenzio Descendants Trust, as well as a separate direct holding of 5,533,794 shares of Common Stock.
CON affiliate Robert A. Ortenzio filed a Form 144 proposing the sale of 130,000 shares of Common Stock with an indicated aggregate amount of $3,250,000.00. The shares were acquired in a private purchase on 04/29/2005, and the filing lists a sale date of 05/08/2026.
Shares outstanding are reported as 127,961,780 as of 06/01/2026, provided here as context; the Form 144 is a routine affiliate notice of an intended resale under SEC procedures.